In Bearbeitung

Bitte warten ...

Einstellungen

Einstellungen

Gehe zu Anmeldung

1. AU2007214085 - Indazole heteroaryl derivatives

Anmerkung: Text basiert auf automatischer optischer Zeichenerkennung (OCR). Verwenden Sie bitte aus rechtlichen Gründen die PDF-Version.

[ EN ]
-72
Patent Claims
1. Compounds selected from the group
- 73
- 74
30 
-75
30 
- 76
- 77
30 
30
35 
0
35 
and pharmaceutically usable derivatives, salts, solvates, tautomers and stereoisomers thereof, including mixtures thereof in all ratios.
- 81
2.       Medicament comprising at least one compound according to Claim 1 and/or pharmaceutically usable derivatives, salts, solvates, tautomers and stereoisomers thereof, including mixtures thereof in all ratios, and optionally excipients and/or adjuvants.
3. Use of compounds according to Claim 1,
and pharmaceutically usable derivatives, salts, solvates, tautomers and stereoisomers thereof, including mixtures thereof in all ratios, for the preparation of a medicament for the treatment of diseases in which the inhibition, regulation and/or modulation of kinase signal transduction plays a role.
4.       Use according to Claim 3, where the kinases are selected from the group of the serine / threonine kinases.
5.       Use according to Claim 4, where the serine / threonine kinases are CHK1 and CHK2.
6.       Use according to Claim 5 of compounds of the formula I according to Claim 1 and pharmaceutically usable derivatives, salts, solvates, tautomers and stereoisorners thereof, including mixtures thereof in all ratios,
for the preparation of a medicament for the treatment of a disease which is influenced by inhibition of the CHK1 and/or CHK2 kinase by the compounds according to Claim 1.
7.        Use according to Claim 6, where the disease to be treated is a prolif erative disorder.
8.        Use according to Claim 7, where the proliferative disorder is a cancer.
- 82
9.       Use according to Claim 8, where a checkpoint pathway in the cancer has been mutated or upregulated.
10.     Use according to Claim 9, where the compound according to Claim 1 is administered in combination with another therapeutic agent.
11.     Use according to Claim 10, where the compound according to Claim
1 and the other therapeutic agent are administered as part of the same pharmaceutical composition.
12.     Use according to Claim 11, where the compound according to Claim
1 and the other therapeutic agent are administered as separate pharmaceutical compositions and the compound according to Claim 1 is administered before, at the same time as or after the administra tion of the other substance.
13.     Use according to Claim 12, where the other therapeutic agent is an anticancer agent.
14.     Use according to Claim 3, where the kinase is SGK.
15.     Use according to Claim 14 of compounds according to Claim 1, and pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios, for the preparation of a medicament for the treatment of diseases which are influenced by inhibition of SGKs by the compounds according to Claim 1.
16.     Use according to Claim 15 of compounds according to Claim 1, and pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios, for the preparation of a medicament for the treatment or prevention of diabetes, obesity, metabolic syndrome (dyslipidaemia), systemic and pulmonary hyper
- 83
tonia, cardiovascular diseases and renal diseases, generally in fibro ses and inflammatory processes of any type, cancer, tumour cells, tumour metastases, coagulopathies, neuronal excitability, glaucoma, cataract, bacterial infections and in antiinfection therapy, for increas ing learning ability and attention, and for the treatment and prophy laxis of cell ageing and stress, and for the treatment of tinnitus.
17.     Use according to Claim 16, where diabetes is diabetes mellitus, dia betic nephropathy, diabetic neuropathy, diabetic angiopathy and microangiopathy.
18.     Use according to Claim 16, where cardiovascular diseases are car diac fibroses after myocardial infarction, cardiac hypertrophy, cardiac insufficiency and arteriosclerosis.
19.     Use according to Claim 16, where renal diseases are glomerulo sclerosis, nephrosclerosis, nephritis, nephropathy and electrolyte excretion disorder.
20.     Use according to Claim 16, where fibroses and inflammatory proc esses are liver cirrhosis, pulmonary fibrosis, fibrosing pancreatitis, rheumatism and arthroses, Crohn's disease, chronic bronchitis, radiation fibrosis, sclerodermatitis, cystic fibrosis, scarring and Alz heimer's disease.
21.     Set (kit) consisting of separate packs of
(a) an effective amount of a compound according to Claim 1 and/or pharmaceutically usable derivatives, solvates and stereo isomers thereof, including mixtures thereof in all ratios,
and
(b) an effective amount of a further medicament active ingredi